These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 36129998)

  • 1. Trial of Antisense Oligonucleotide Tofersen for
    Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
    N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
    Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
    N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
    Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
    Oliveira Santos M; de Carvalho M
    Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18 months.
    Meyer T; Schumann P; Weydt P; Petri S; Weishaupt JH; Weyen U; Koch JC; Günther R; Regensburger M; Boentert M; Wiesenfarth M; Koc Y; Kolzarek F; Kettemann D; Norden J; Bernsen S; Elmas Z; Conrad J; Valkadinov I; Vidovic M; Dorst J; Ludolph AC; Hesebeck-Brinckmann J; Spittel S; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2024 Sep; 70(3):333-345. PubMed ID: 39031772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients.
    Sabatelli M; Cerri F; Zuccarino R; Patanella AK; Bernardo D; Bisogni G; Tanel R; Sansone V; Filosto M; Lattante S; Martello F; Doronzio PN; Stano S; Zanfini BA; Coccia M; Costantini EM; Lizio A; Lucioli G; Padovani A; Merlini GP; Conte A
    J Neurol; 2024 Aug; 271(8):5177-5186. PubMed ID: 38829431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
    Benatar M; Wuu J; Andersen PM; Bucelli RC; Andrews JA; Otto M; Farahany NA; Harrington EA; Chen W; Mitchell AA; Ferguson T; Chew S; Gedney L; Oakley S; Heo J; Chary S; Fanning L; Graham D; Sun P; Liu Y; Wong J; Fradette S
    Neurotherapeutics; 2022 Jul; 19(4):1248-1258. PubMed ID: 35585374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [SOD1 gene therapy delays ALS disease progression].
    Forsberg K; Karlsborg M; Salvesen L; Svenstrup K; Winroth I; Berntsson H; M Andersen P
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38666665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of tofersen treatment in patients with
    Wiesenfarth M; Dorst J; Brenner D; Elmas Z; Parlak Ö; Uzelac Z; Kandler K; Mayer K; Weiland U; Herrmann C; Schuster J; Freischmidt A; Müller K; Siebert R; Bachhuber F; Simak T; Günther K; Fröhlich E; Knehr A; Regensburger M; German A; Petri S; Grosskreutz J; Klopstock T; Reilich P; Schöberl F; Hagenacker T; Weyen U; Günther R; Vidovic M; Jentsch M; Haarmeier T; Weydt P; Valkadinov I; Hesebeck-Brinckmann J; Conrad J; Weishaupt JH; Schumann P; Körtvélyessy P; Meyer T; Ruf WP; Witzel S; Senel M; Tumani H; Ludolph AC
    EClinicalMedicine; 2024 Mar; 69():102495. PubMed ID: 38384337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.
    Miller TM; Pestronk A; David W; Rothstein J; Simpson E; Appel SH; Andres PL; Mahoney K; Allred P; Alexander K; Ostrow LW; Schoenfeld D; Macklin EA; Norris DA; Manousakis G; Crisp M; Smith R; Bennett CF; Bishop KM; Cudkowicz ME
    Lancet Neurol; 2013 May; 12(5):435-42. PubMed ID: 23541756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
    ;
    Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofersen for SOD1 ALS.
    Everett WH; Bucelli RC
    Neurodegener Dis Manag; 2024; 14(5):149-160. PubMed ID: 39330700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofersen: First Approval.
    Blair HA
    Drugs; 2023 Jul; 83(11):1039-1043. PubMed ID: 37316681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.
    Lange DJ; Shahbazi M; Silani V; Ludolph AC; Weishaupt JH; Ajroud-Driss S; Fields KG; Remanan R; Appel SH; Morelli C; Doretti A; Maderna L; Messina S; Weiland U; Marklund SL; Andersen PM
    Ann Neurol; 2017 Jun; 81(6):837-848. PubMed ID: 28480639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study.
    van den Berg LH; Rothstein JD; Shaw PJ; Babu S; Benatar M; Bucelli RC; Genge A; Glass JD; Hardiman O; Libri V; Mobach T; Oskarsson B; Pattee GL; Ravits J; Shaw CE; Weber M; Zinman L; Jafar-Nejad P; Rigo F; Lin L; Ferguson TA; Gotter AL; Graham D; Monine M; Inra J; Sinks S; Eraly S; Garafalo S; Fradette S
    Lancet Neurol; 2024 Sep; 23(9):901-912. PubMed ID: 39059407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
    Saini A; Chawla PA
    Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients.
    Weishaupt JH; Körtvélyessy P; Schumann P; Valkadinov I; Weyen U; Hesebeck-Brinckmann J; Weishaupt K; Endres M; Andersen PM; Regensburger M; Dreger M; Koch JC; Conrad J; Meyer T
    Commun Med (Lond); 2024 Jul; 4(1):150. PubMed ID: 39054363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy.
    Winer L; Srinivasan D; Chun S; Lacomis D; Jaffa M; Fagan A; Holtzman DM; Wancewicz E; Bennett CF; Bowser R; Cudkowicz M; Miller TM
    JAMA Neurol; 2013 Feb; 70(2):201-7. PubMed ID: 23147550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inclusions in macrophages of the cerebrospinal fluid during treatment with Tofersen.
    Sparasci D; Castelli C; Staedler C; Gobbi C; Ripellino P
    Muscle Nerve; 2023 Feb; 67(2):E3-E5. PubMed ID: 36477882
    [No Abstract]   [Full Text] [Related]  

  • 20. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
    Paganoni S; Macklin EA; Hendrix S; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson T; Jackson CE; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha S; Miller TM; Scelsa SN; Vu TH; Fournier CN; Glass JD; Johnson KM; Swenson A; Goyal NA; Pattee GL; Andres PL; Babu S; Chase M; Dagostino D; Dickson SP; Ellison N; Hall M; Hendrix K; Kittle G; McGovern M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; Tustison E; Vigneswaran P; Walker J; Yu H; Chan J; Wittes J; Cohen J; Klee J; Leslie K; Tanzi RE; Gilbert W; Yeramian PD; Schoenfeld D; Cudkowicz ME
    N Engl J Med; 2020 Sep; 383(10):919-930. PubMed ID: 32877582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.